KAI Pharmaceuticals Acquired By Amgen For $315M
South San Francisco-based KAI Pharmaceuticals, a biopharmaceuticals firm development treatment of secondary hyperparathroidism in patients with chronic kidney disease on dialysis, has been acquired by Amgen, the firms said today. Amgen said it would pay $315M in cash for KAI Pharmaceuticals, which was venture backed by InterWest Partners, Skyline Ventures, Intersouth Partners, Aberdare Ventures, Investor Growth Capital, Kearny Venture Partners, Lumira Capital and Delphi Ventures.
posted on Tuesday, April 10, 2012
Related companies:
Kai Medical, Inc.
Related stories:
> Onyx Pharmaceuticals Acquired By Amgen For $10.4 Billion
> venBio Raises $315M Life Science Investment Fund
> Gilead Sciences Buys Calistoga Pharmaceuticals
> Alexza Pharmaceuticals Acquired By Ferrer
> Avidia Acquired by Amgen
silicontap.com Home